ArticleScientific reports2026
Curcumin-stabilized silver nanoparticles target the Helicobacter pylori-tumor interface in gastric cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains a major global health burden, ranking among the leading causes of cancer-related mortality worldwide. Chronic infection with Helicobacter pylori is a well-established etiological factor, promoting sustained gastric inflammation, epithelial transformation, and tumor progression through modulation of the gastric microenvironment. Therapeutic strategies that simultaneously target microbial virulence and tumor cell survival remain limited. In this study, we developed curcumin-stabilized silver nanoparticles (AgNPs) as a dual-functional nanoformulation designed to modulate the tumor-associated microbiome while exerting direct anti-cancer effects. The nanoparticles were chemically synthesized with a controlled diameter of 15 ± 2 nm, enabling enhanced surface reactivity and biological interaction. Antimicrobial evaluation revealed potent activity against H. pylori, with an IC
Indexed as
Identifiers
42236864What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.